Literature DB >> 26491160

Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1.

Duosha Hu1, Victoria Wang1, Min Yang1, Shahed Abdullah2, David A Davis1, Thomas S Uldrick1, Mark N Polizzotto1, Ravindra P Veeranna1, Stefania Pittaluga2, Giovanna Tosato3, Robert Yarchoan4.   

Abstract

UNLABELLED: Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a subset of multicentric Castleman disease (MCD). The KSHV life cycle has two principal gene repertoires, latent and lytic. KSHV viral interleukin-6 (vIL-6), an analog of human IL-6, is usually lytic; production of vIL-6 by involved plasmablasts is a central feature of KSHV-MCD. vIL-6 also plays a role in PEL and KS. We show that a number of plasmablasts from lymph nodes of patients with KSHV-MCD express vIL-6 but not ORF45, a KSHV lytic gene. We further show that vIL-6 is directly induced by the spliced (active) X-box binding protein-1 (XBP-1s), a transcription factor activated by endoplasmic reticulum (ER) stress and differentiation of B cells in lymph nodes. The promoter region of vIL-6 contains several potential XBP-response elements (XREs), and two of these elements in particular mediate the effect of XBP-1s. Mutation of these elements abrogates the response to XBP-1s but not to the KSHV replication and transcription activator (RTA). Also, XBP-1s binds to the vIL-6 promoter in the region of these XREs. Exposure of PEL cells to a chemical inducer of XBP-1s can induce vIL-6. Patient-derived PEL tumor cells that produce vIL-6 frequently coexpress XBP-1, and immunofluorescence staining of involved KSHV-MCD lymph nodes reveals that most plasmablasts expressing vIL-6 also coexpress XBP-1. These results provide evidence that XBP-1s is a direct activator of KSHV vIL-6 and that this is an important step in the pathogenesis of KSHV-MCD and PEL. IMPORTANCE: Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is characterized by severe inflammatory symptoms caused by an excess of cytokines, particularly KSHV-encoded viral interleukin-6 (vIL-6) produced by lymph node plasmablasts. vIL-6 is usually a lytic gene. We show that a number of KSHV-MCD lymph node plasmablasts express vIL-6 but do not have full lytic KSHV replication. Differentiating lymph node B cells express spliced (active) X-box binding protein-1 (XBP-1s). We show that XBP-1s binds to the promoter of vIL-6 and can directly induce production of vIL-6 through X-box protein response elements on the vIL-6 promoter region. We further show that chemical inducers of XBP-1s can upregulate production of vIL-6. Finally, we show that most vIL-6-producing plasmablasts from lymph nodes of KSHV-MCD patients coexpress XBP-1s. These results demonstrate that XBP-1s can directly induce vIL-6 and provide evidence that this is a key step in the pathogenesis of KSHV-MCD and other KSHV-induced diseases.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26491160      PMCID: PMC4702535          DOI: 10.1128/JVI.01192-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Authors:  Mark N Polizzotto; Thomas S Uldrick; Victoria Wang; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Stefania Pittaluga; Deirdre O'Mahony; Denise Whitby; Giovanna Tosato; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

2.  Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus.

Authors:  Y Aoki; M Narazaki; T Kishimoto; G Tosato
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

3.  Viral IL-6-induced cell proliferation and immune evasion of interferon activity.

Authors:  Malini Chatterjee; Julie Osborne; Giovanna Bestetti; Yuan Chang; Patrick S Moore
Journal:  Science       Date:  2002-11-15       Impact factor: 47.728

4.  IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA.

Authors:  Marcella Calfon; Huiqing Zeng; Fumihiko Urano; Jeffery H Till; Stevan R Hubbard; Heather P Harding; Scott G Clark; David Ron
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

5.  Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders.

Authors:  Y Aoki; R Yarchoan; K Wyvill; S Okamoto ; R F Little; G Tosato
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

6.  XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor.

Authors:  H Yoshida; T Matsui; A Yamamoto; T Okada; K Mori
Journal:  Cell       Date:  2001-12-28       Impact factor: 41.582

7.  Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus.

Authors:  D A Davis; A S Rinderknecht; J P Zoeteweij; Y Aoki; E L Read-Connole; G Tosato; A Blauvelt; R Yarchoan
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

8.  Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis.

Authors:  Fu-Chun Zhou; Yan-Jin Zhang; Jian-Hong Deng; Xin-Ping Wang; Hong-Yi Pan; Evelyn Hettler; Shou-Jiang Gao
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

9.  Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1.

Authors:  Neal N Iwakoshi; Ann-Hwee Lee; Prasanth Vallabhajosyula; Kevin L Otipoby; Klaus Rajewsky; Laurie H Glimcher
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

10.  Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator.

Authors:  Hiroyuki Nakamura; Michael Lu; Yousang Gwack; John Souvlis; Steven L Zeichner; Jae U Jung
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more
  11 in total

Review 1.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

2.  Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1.

Authors:  Victoria Wang; David A Davis; Claire Deleage; Catherine Brands; Hong S Choi; Muzammel Haque; Robert Yarchoan
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

Review 3.  HIV-associated Kaposi sarcoma and related diseases.

Authors:  Priscila H Gonçalves; Thomas S Uldrick; Robert Yarchoan
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

Review 4.  Immunotherapy for KSHV-associated diseases.

Authors:  Kathryn Lurain; Robert Yarchoan; Ramya Ramaswami
Journal:  Curr Opin Virol       Date:  2022-07-05       Impact factor: 7.121

Review 5.  Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease.

Authors:  Kathryn Lurain; Robert Yarchoan; Thomas S Uldrick
Journal:  Hematol Oncol Clin North Am       Date:  2018-02       Impact factor: 3.722

6.  RUNX1 Plays an Important Role in Mediating BMP9-Induced Osteogenic Differentiation of Mesenchymal Stem Cells Line C3H10T1/2, Murine Multi-Lineage Cells Lines C2C12 and MEFs.

Authors:  Caixia Ji; Xiaohua Liu; Li Xu; Tingting Yu; Chaoqun Dong; Jinyong Luo
Journal:  Int J Mol Sci       Date:  2017-06-23       Impact factor: 5.923

Review 7.  Herpesviruses and the Unfolded Protein Response.

Authors:  Benjamin P Johnston; Craig McCormick
Journal:  Viruses       Date:  2019-12-21       Impact factor: 5.048

8.  Analysis of KSHV B lymphocyte lineage tropism in human tonsil reveals efficient infection of CD138+ plasma cells.

Authors:  Farizeh Aalam; Romina Nabiee; Jesus Ramirez Castano; Jennifer Totonchy
Journal:  PLoS Pathog       Date:  2020-10-19       Impact factor: 6.823

9.  Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide.

Authors:  David A Davis; Suraj Mishra; Holda A Anagho; Ashley I Aisabor; Prabha Shrestha; Victoria Wang; Yuki Takamatsu; Kenji Maeda; Hiroaki Mitsuya; Jerome B Zeldis; Robert Yarchoan
Journal:  Oncotarget       Date:  2017-05-17

10.  KSHV activates unfolded protein response sensors but suppresses downstream transcriptional responses to support lytic replication.

Authors:  Benjamin P Johnston; Eric S Pringle; Craig McCormick
Journal:  PLoS Pathog       Date:  2019-12-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.